Acalabrutinib is a second-generation irreversible inhibitor of Bruton's tyrosine kinase (BTK), belonging to the imidazopyrazine class. It is an active pharmaceutical ingredient used in the manufacturing of products for oncology research and development.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Acalabrutinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Acalabrutinib maleate
pharmaceutical raw material
Calquence
pharmaceutical raw material
Pirtobrutinib
pharmaceutical raw material
(S)-2-((1-Benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one hydrochloride
pharmaceutical raw material
15-epi travoprost
pharmaceutical raw material
Mutated EGFR-IN-1
pharmaceutical raw material
Osimertinib
pharmaceutical raw material
Acalabrutinib enantiomer
pharmaceutical raw material
The international HS code for Acalabrutinib (CAS 1420477-60-6) is 2933.39.
2933.39
2933 39 99
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide
WDENQIQQYWYTPO-IBGZPJMESA-N
CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5
Sourcing Acalabrutinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.